Skip to main content
. 2021 Apr 19;2021(4):CD011535. doi: 10.1002/14651858.CD011535.pub4

14.

14

Ranking for all the outcomes at class level

AIL12/23: anti‐IL12/23; AIL17: anti‐IL17; AIL23: anti‐IL23, ATA: anti‐TNF alpha; CSA: non‐biological conventional systemic agents; PBO: placebo; SM: small molecules

AE: adverse events; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment; QoL: quality of life; SAE: serious adverse events; SAE without worsening of psoriasis correspond to SAE after exclusion of flares of psoriasis